Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v2-FR Version v1-EN
Language French English
Date Updated 2021-08-23 2021-08-23
Drug Identification Number 02358336 02358336
Brand name IMIPENEM AND CILASTATIN FOR INJECTION USP IMIPENEM AND CILASTATIN FOR INJECTION USP
Common or Proper name IMIPENEM AND CILASTATIN FOR INJECTION USP IMIPENEM AND CILASTATIN FOR INJECTION USP
Company Name SANDOZ CANADA INCORPORATED SANDOZ CANADA INCORPORATED
Ingredients CILASTATIN IMIPENEM CILASTATIN IMIPENEM
Strength(s) 250MG 250MG 250MG 250MG
Dosage form(s) POWDER FOR SOLUTION POWDER FOR SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS INTRAVENOUS INTRAVENOUS
Packaging size 10PSOIJ CA 10PSOIJ CA
ATC code J01DH J01DH
ATC description OTHER BETA-LACTAM ANTIBACTERIALS OTHER BETA-LACTAM ANTIBACTERIALS
Reason for discontinuation Business reasons Business reasons
Anticipated discontinuation date
Actual discontinuation date 2021-08-20 2021-08-20
Remaining supply date 2021-08-20 2021-08-20
Discontinuation status Discontinued Discontinued
Discontinuation decision reversal no no
Tier 3 Status No No
Information on remaining supply
Company comments
Health Canada comments